| 0.3701 -0.007 (-1.78%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.56 | 1-year : | 0.65 |
| Resists | First : | 0.48 | Second : | 0.55 |
| Pivot price | 0.45  |
|||
| Supports | First : | 0.37 | Second : | 0.3 |
| MAs | MA(5) : | 0.39 |
MA(20) : | 0.47 |
| MA(100) : | 0.59 |
MA(250) : | 0.83 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 7.4 |
D(3) : | 10  |
| RSI | RSI(14): 22.9 |
|||
| 52-week | High : | 1.69 | Low : | 0.37 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MBIO ] has closed above bottom band by 6.1%. Bollinger Bands are 52.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.43 - 0.43 | 0.43 - 0.43 |
| Low: | 0.36 - 0.37 | 0.37 - 0.37 |
| Close: | 0.37 - 0.37 | 0.37 - 0.37 |
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Tue, 13 Oct 2026
Mustang Bio stock sits 2.70 percent above its yearly low - ad-hoc-news.de
Tue, 06 Oct 2026
MBIO stock sits near its 52-week low as Nasdaq deadline nears - ad-hoc-news.de
Wed, 02 Sep 2026
Mustang Bio Inc. (MBIO) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Wed, 15 Jul 2026
Mustang Bio Inc. (MBIO) Q4 2024 Earnings: Significant EPS Miss Amidst Ongoing Operational Challenges - Tech Earnings Analysis - www.dars.gov.et
Fri, 13 Feb 2026
MBIO Should I Buy - Intellectia AI
Fri, 28 Mar 2025
Mustang Bio Inc. (MBIO) reports earnings - qz.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 8 (%) |
| Held by Institutions | 9.9 (%) |
| Shares Short | 53 (K) |
| Shares Short P.Month | 55 (K) |
| EPS | -0.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -15.4 % |
| Return on Equity (ttm) | -58.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.53 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.85 |
| PEG Ratio | 0 |
| Price to Book value | 0.37 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.56 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|